SoftOx Solutions AS logo

SoftOx Solutions AS (SOFTX)

Market Open
10 Aug, 14:20
XOSL XOSL
kr
0. 08
-0
-2.8037%
kr
105.72M Market Cap
- P/E Ratio
- Div Yield
10.84M Volume
0 Eps
kr 0.09
Previous Close
Add Transaction
Day Range
0.08 0.09
Year Range
0 0
Want to track SOFTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

SOFTX trading today lower at kr0.08, a decrease of -2.8037% from yesterday's close, completing a monthly increase of 0% or kr0.08. Over the past 12 months, SOFTX stock gained 0%.
SOFTX is not paying dividends to its shareholders.
The last earnings report, released on Jun 20, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

SOFTX Chart

SoftOx Solutions AS (SOFTX) FAQ

What is the stock price today?

The current price is kr0.08.

On which exchange is it traded?

SoftOx Solutions AS is listed on XOSL.

What is its stock symbol?

The ticker symbol is SOFTX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 105.72M.

Has SoftOx Solutions AS ever had a stock split?

No, there has never been a stock split.

SoftOx Solutions AS Profile

Biotechnology Industry
Healthcare Sector
Mr. Thomas Bjarnsholt CEO
XOSL Exchange
NO0010811961 ISIN
Norway Country
2 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

SoftOx Solutions AS is a pioneering enterprise positioned at the intersection of medtech and pharmaceutical domains, with its roots planted firmly in Norway. This entity, alongside its subsidiaries, embarks upon the mission of addressing a plethora of healthcare challenges through the development and distribution of innovative disinfection and infection treatment solutions. The foundation of the company was laid in 2012, with its headquarters established in Fornebu, Norway. It is geared towards the creation of products that not only combat a wide array of pathogens including bacteria, viruses, and fungi but also cater to the need for skin-friendly disinfectants. Moreover, SoftOx Solutions AS is actively involved in the research and development of groundbreaking treatments for both human and animal health, highlighting its commitment to advancing healthcare across species.

Products and Services

  • SafeDes+: A specialized hand disinfectant designed with the needs of individuals with irritated, compromised, and eczematous skin in mind. This product stands out for its compatibility with sensitive skin, providing a solution that disinfects without exacerbating skin conditions.
  • EffectDesH: A potent surface disinfectant acknowledged for its wide-ranging inactivation capabilities. EffectDesH is effective against bacteria, viruses, yeast, fungi, mycobacterium, and spores, ensuring a comprehensive disinfection solution for various environments.
  • SoftOx Wound Irrigation Solutions: These solutions are meticulously formulated for both acute and chronic wounds to preempt and combat infections, including the challenging biofilms. Their application in wound care showcases SoftOx's dedication to facilitating healing and preventing infection with innovative approaches.
  • SoftOx Anti-infectives: Targeted at treating and eradicating topical infections across wounded and mucosal tissues, these anti-infectives are formidable against biofilms, AMR microbes, viruses, and fungi. Their development is a testament to SoftOx's relentless pursuit of new solutions in the fight against resistant pathogens.
  • Antiseptic Solutions for Pets and Livestock: Expanding its horizon beyond human healthcare, SoftOx is also developing antiseptic solutions tailored for pets and livestock. This initiative underscores the company's recognition of the interconnectedness of human and animal health.
  • Inhalation Solution: Embarking on a venture into respiratory health, this novel inhaled drug is being developed for the early treatment and prevention of influenza-like illnesses. It represents a self-administered solution aiming to offer a preemptive shield against respiratory infections.

Contact Information

Address: Martin Linges vei 25
Phone: 47 91 87 61 65